ArticleGalen medical journal2025
Tumor Characteristics and D2 Lymph Node Involvement in Gastric Cancer: A Clinicopathological Analysis (2018-2023) :.
Article in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric adenocarcinoma is a leading cause of cancer-related mortality worldwide, with lymph node involvement, particularly at the level 2 lymph node dissection (D2), serving as a critical determinant of prognosis and surgical strategy. This study aimed to evaluate the association between primary tumor characteristics and D2 lymph node involvement and examine these factors' impact on overall survival (OS) and disease-free survival (DFS) in patients undergoing curative gastrectomy. Materials and Methods: A retrospective cohort study was conducted on 233 patients with histologically confirmed gastric cancer who underwent curative-intent surgery at Namazi Hospital (Shiraz, Iran) between April 2018 and March 2023. Clinicopathological variables, including tumor size, location, grade, and histologic type, were assessed with D2 lymph node involvement. Survival outcomes were analyzed using Kaplan- Meier estimates and compared using the log-rank test. Multivariate logistic regression and Cox proportional hazards models were employed to identify independent nodal involvement and survival predictors. Results: D2 lymphadenectomy in 38.1% of patients indicated no significant associations between D2 involvement and tumor grade (P=0.443), size (P=0.215), or location (P=0.522). However, D2 lymph node metastasis was associated with a significantly descending mean of overall survival (25.43 ± 3.36 months) compared to patients without D2 involvement (43.06 ± 2.59 months; P0.001). Tumor stage and size were strong predictors of survival, with Stage 3C patients revealing a median overall survival of 13.45 months and tumors 3 cm being associated with superior outcomes (P=0.002). Conclusion: D2 lymph node involvement reflects progressive disease biology and is an assertive prognostic marker in gastric adenocarcinoma. While tumor grade, size, and location were not independently predictive of D2 metastasis, tumor stage and nodal status were strongly associated with survival. These results reinforce the use of extended lymphadenectomy in selected patients and underscore the requirement for individualized surgical planning based on total tumor profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.